Affinity maturation of CRISPR-engineered B cell receptors in vivo.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 38509393.
- Also identified by DOI 10.1038/s41551-024-01184-9 and PMC identifier 12125666.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
CRISPR-Cas12a was used to directly replace mouse antibody variable chain genes with human versions in primary B cells. The edited cells underwent affinity maturation in vivo, improving the potency of HIV-1 and SARS-CoV-2 neutralizing antibodies without loss of bioavailability.
Medical subject headings
- CRISPR-Cas Systems
- Receptors, Antigen, B-Cell